(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Instructions to Keep up with Your Traded Teeth for Life span - 2African nations push to recognize crimes of colonialism in Algeria
- 3Flu is rising rapidly, driven by a new variant. Here's what to know
- 4The Artemis II launch is tonight. Here's how to watch it live.
- 5Inn The executives: A Remunerating Profession Decision for Energetic People
- The Benefits of Rehearsing Careful Nurturing
- Poland open to German troops to help secure Ukraine ceasefire
- More Than 110 New Species Discovered In Deep Waters Off Australia
- Optimal Beauty Parlor Medicines for Upgraded Wellbeing and Appearance
- Experience Unrivaled Sound: Top Speakers You Really want to Hear
- ByHeart sued over recalled formula by parents of infants sickened with botulism
- Pick Your Number one sort of blossom
- 'Fertiliser costs mean I'm better off not planting'
- Mexico says a third of 130,000 missing people might be alive, fueling criticisms by families
